DOWN SYNDROME IS THE MOST COMMON CHROMOSOMAL DISORDER ASSOCIATED WITH SKIN CONDITIONS, INCLUDING PSORIASIS AND HIDRADENITIS SUPPURATIVA. PATIENTS WITH DOWN SYNDROME ARE MORE LIKELY TO BE OVERWEIGHT OR OBSESE AND DIAGNOSED WITH METABOLIC COMORBIDITIES SUCH AS CARDIOVASCULAR DISORDERS, INFLAMMATORY JOINT DISEASES AS IN PSORIASIS AND HIDRADENITIS SUPPURATIVA. ALTHOUGH BOTH HIDRADENITIS SUPPURATIVA AND PSORIASIS ARE ASSOCIATED WITH DOWN SYNDROME, CONCURRENT PSORIASIS AND HIDRADENITIS SUPPURATIVA IN THE SAME PATIENT WITH DOWN SYNDROME HAVE NOT BEEN REPORTED IN THE LITERATURE. HERE, WE DESCRIBE THREE PATIENTS WITH DOWN SYNDROME HAVING BOTH HIDRADENITIS SUPPURATIVA AND PSORIASIS BY DISCUSSING THE COMMON ETIOPATHOGENESIS CONSIDERING THE CURRENT LITERATURE.
Case Presentation

The demographic and clinical characteristics of three patients with Down syndrome who had also been diagnosed with both psoriasis and hidradenitis suppurativa are provided in Table 1. All patients were male, obese with a body mass index over 30 kg/m², and had congenital thyroid disorders in common. Case 1 had epilepsy and recurrent lower respiratory tract infections. Case 2 had a history of acute lymphoblastic leukemia and familial Mediterranean fever. None of the patients had a family history of hidradenitis suppurativa or psoriasis. The severity of hidradenitis suppurativa was Hurley stage 2 in case 1 and case 3, and Hurley stage 1 in case 2. The type of psoriasis was plaque-type in all patients. Figures 1 and 2 represent the lesions of the hidradenitis suppurativa and psoriasis of Case 1, respectively. Previous treatments of the patients for hidradenitis suppurativa and psoriasis are shown in Table 1. Case 1 was given oral acitretin with a dose of 25 mg/kg per day and the psoriatic lesions improved significantly, but hidradenitis suppurativa lesions did not show sufficient improvement in the three-month period of the treatment. Cases 2 and 3 have been under topical corticosteroid treatment for psoriasis with excellent response. Case 2 benefited from topical clindamycin 2% solution for hidradenitis suppurativa lesions, while oral doxycycline 200 mg BID treatment showed efficacy in case 3.

Table 1. Demographic and clinical characteristics of the patients with Down syndrome having both hidradenitis suppurativa and psoriasis

| Characteristics                  | Case 1                | Case 2                | Case 3                |
|----------------------------------|-----------------------|-----------------------|-----------------------|
| Age (years)/gender               | 27/male               | 24/male               | 20/male               |
| Body mass index (kg/m²)          | 34.2                  | 32                    | 42.6                  |
| Family history for hidradenitis suppurativa | No                    | No                    | No                    |
| Onset of hidradenitis suppurativa | 17 years old          | 15 years old          | 19 years old          |
| Hidradenitis involvement         | Axilla, inguinal folds, abdomen, pubic and intergluteal region | Back                  | Axilla, intergluteal region |
| Hurley stage of hidradenitis suppurativa | 2                    | 1                     | 2                     |
| Family history of psoriasis      | No                    | No                    | No                    |
| Onset of psoriasis               | 13 years old          | 20 years old          | 18 years old          |
| Type of psoriasis                | Vulgaris              | Vulgaris              | Vulgaris              |
| Psoriasis involvement            | Dorsum of the hands and feet, bilateral shins, fingernails, and toenails | Dorsum of the hands and fingers, bilateral elbows | Dorsum of the hands, bilateral elbows |
| PASI score                       | 8                     | 1.6                   | 1.8                   |
| Comorbidities                    | Epilepsy, hypothyroidism, Recurrent lower respiratory tract infections | ALL, FMF, hyperthyroidism | Hypothyroidism |
| Concomitant treatments           | Levothyroxine, levetiracetam, sodium valproate | Allopurinol, colchicine | Levothyroxine |

ALL: Acute lymphoblastic leukemia, FMF: Familial Mediterranean Fever, PASI: Psoriasis area severity index

Discussion

Hidradenitis suppurativa is one of the most common skin disorders in patients with Down syndrome, and the risk of hidradenitis suppurativa is five times higher in patients with Down syndrome than in the normal population (5,6). It has been shown that Down syndrome-related hidradenitis suppurativa appears earlier in life and shows a mild or moderate disease course as in current cases staged as Hurley 1 and 2 (7). The genetic background of hidradenitis suppurativa is based on disrupted notch signaling due to loss-of-function mutations in the genes encoding gamma-secretase transmembranous enzyme complex (8). Blok et al. (9) have suggested that the association between hidradenitis suppurativa and Down syndrome results from the overexpression of the amyloid precursor protein (APP) gene, located on chromosome 21. APP and notch receptors are competitive substrates for the gamma-secretase transmembranous enzyme complex. Thus, increased APP expression may lead to the disruption of notch signaling. Increased expression of APP and consequent notch signaling impairment may stimulate impaired keratinocyte adhesion, migration, and proliferation, causing follicular plugging, which is thought to play a significant role in hidradenitis suppurativa pathogenesis (9). Besides, impaired notch signaling pathways may contribute to the dysregulation of the inflammatory response in patients with hidradenitis suppurativa and Down syndrome.
Psoriasis is an immune-mediated and chronic inflammatory skin disorder (10). The frequency of psoriasis in patients with Down syndrome has been demonstrated to be approximately 9% (2,6). As these data are based solely on case studies, the relationship between psoriasis and Down syndrome remains to be elucidated. It has been proposed that the high frequency of psoriasis in patients with Down syndrome is related to elevated serum levels of tumor necrosis factor (TNF)-alpha, interleukin (IL)-1 beta, and interferon (IFN)-gamma (4). All of which are thought to be involved in psoriasis pathogenesis and high serum levels of INF-gamma and increased sensitivity to IFN-gamma due to chromosome 21 ploidy in patients with Down syndrome (3).

The IL-23/Th17 and TNF-alpha pathways are common in the molecular pathogenesis of psoriasis and hidradenitis suppurativa. Further, psoriasis and hidradenitis suppurativa share common aggravating factors and comorbidities such as smoking, obesity, and metabolic syndrome (4). Patients with the dual diagnosis of hidradenitis suppurativa and psoriasis have been revealed to have a higher prevalence of obesity (4,11). Obesity occurs in more than 50% of adults with Down syndrome (1). Thus, the association between Down syndrome, hidradenitis suppurativa, and psoriasis may be attributed to the common pathophysiological mechanisms: dysregulated notch signaling and inflammatory mechanisms, and obesity.
Psoriasis and hidradenitis suppurativa share common therapeutic options due to similarities in their pathogenic mechanisms (4). As patients with Down syndrome have a mild severity of hidradenitis suppurativa and psoriasis, treatment with topical corticosteroids and antibiotics may be sufficient to control the diseases (7). Oral acitretin and adalimumab, showing high efficacy on both hidradenitis suppurativa and psoriasis, may be required options in recalcitrant and moderate to severe cases (11,12). However, comorbidities requiring multiple medications and a dysregulated immune system ensuing susceptibility to infections and malignancies in Down syndrome may restrict treatment options (1). Dermatologists should exercise caution, and close follow-up should be recommended when using these treatments in patients with Down syndrome.

Conclusion

In conclusion, the coexistence of hidradenitis suppurativa and psoriasis in patients with Down syndrome is rare but should be kept in mind. Patients with Down syndrome should be carefully examined for accompanying dermatologic disorders. The management of the condition is challenging; hence, patients should be monitored closely after appropriate treatment selection.

Ethics

Informed Consent: Consent form was filled out by all participants.

Peer-review: Externally peer-reviewed.

Authorship Contributions

Surgical and Medical Practices - Concept - Design - Data Collection or Processing - Analysis or Interpretation - Literature Search - Writing: N.D.Ö., P.E., E.Ç.

Conflict of Interest: No conflict of interest was declared by the authors.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Bull MJ. Down Syndrome. N Engl J Med. 2020;382:2344-2352.
2. Firsowicz M, Boyd M, Jacks SK. Follicular occlusion disorders in Down syndrome patients. Pediatr Dermatol. 2020;37:219-221.
3. Marmon S, De Souza A, Strober BE. Psoriasis and Down syndrome: a report of three cases and a potential pathophysiologic link. Dermatol Online J. 2012;18:13.
4. Kridin K, Shani M, Schonmann Y, et al. Psoriasis and Hidradenitis Suppurativa: A Large-scale Population-based Study. J Am Acad Dermatol. 2018:0190-9622.
5. Garg A, Strunk A, Midura M, Papagermanos V, Pomerantz H. Prevalence of hidradenitis suppurativa among patients with Down syndrome: a population-based cross-sectional analysis. Br J Dermatol. 2018;178:697-703.
6. Rork JF, McCormack L, Lal K, Wiss K, Belazarian L. Dermatologic conditions in Down syndrome: A single-center retrospective chart review. Pediatr Dermatol. 2020;37:811-816.
7. Giovannardi G, Chiricozzi A, Bianchi L, et al. Hidradenitis Suppurativa Associated with Down Syndrome Is Characterized by Early Age at Diagnosis. Dermatology. 2018;234:66-70.
8. Jfri AH, O’Brien EA, Litvinov IV, Alavi A, Netchiporouk E. Hidradenitis Suppurativa: Comprehensive Review of Predisposing Genetic Mutations and Changes. J Cutan Med Surg. 2019;23:519-527.
9. Blok J, Jonkman M, Horváth B. The possible association of hidradenitis suppurativa and Down syndrome: is increased amyloid precursor protein expression resulting in impaired Notch signalling the missing link?. Br J Dermatol. 2014;170:1375-1377.
10. Armstrong AW, Read C. Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review. JAMA. 2020;323:1945-1960.
11. Pinter A, Sarlak M, Zeiner KN, et al. Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern. Dermatology. 2021;237:759-768.
12. Orenstein LAV, Nguyen TV, Damiani G, Sayed C, Jemec GBE, Hamzavi I. Medical and Surgical Management of Hidradenitis Suppurativa: A Review of International Treatment Guidelines and Implementation in General Dermatology Practice. Dermatology. 2020;236:393-412.